Danahervs.Revvity
DHR vs RVTY · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Danaher is about 8.9× larger than Revvity by market cap; Danaher trades at the lower P/E (38.5 vs 72.6); year to date, Revvity leads (+57.3% vs −5.0%).
Side by side
| DHR | RVTY | |
|---|---|---|
| Market cap | $154B | $17.2B |
| Price | $219.81 | $154.18 |
| Today | +1.1% | +1.3% |
| Return YTD | −5.0% | +57.3% |
| Return 1Y | +6.1% | +65.8% |
| Since June 26, 2026 | +12.0% | +36.4% |
| P/E | 38.5 | 72.6 |
| P/S | 6.1 | 5.9 |
| P/B | 2.9 | 2.4 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
DanaherDHR
Cytiva supplies the equipment biologics are made with; Cepheid runs molecular diagnostics. Danaher owns both, along with a wider set of life science instruments.
Full DHR profile →RevvityRVTY
Newborn and genetic screening is the clinical end of the business; the rest supplies reagents and software to research laboratories.
Full RVTY profile →More DHR & RVTY comparisons
Other head-to-heads in the Life science tools segment.